FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380680905> ?p ?o ?g. }

• W4380680905 abstract "Metastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refractory. Elacestrant, a new generation FDA-approved oral selective estrogen receptor degrader (SERD) and antagonist, has demonstrated efficacy in a subset of women with advanced HR+breast cancer, but there are few patient-derived models to characterize its effect in advanced cancers with diverse treatment histories and acquired mutations.We analyzed clinical outcomes with elacestrant, compared with endocrine therapy, among women who had previously been treated with a fulvestrant-containing regimen from the recent phase 3 EMERALD Study. We further modeled sensitivity to elacestrant, compared with the currently approved SERD, fulvestrant in patient-derived xenograft (PDX) models and cultured circulating tumor cells (CTCs).Analysis of the subset of breast cancer patients enrolled in the EMERALD study who had previously received a fulvestrant-containing regimen indicates that they had better progression-free survival with elacestrant than with standard-of-care endocrine therapy, a finding that was independent estrogen receptor (ESR1) gene mutations. We modeled elacestrant responsiveness using patient-derived xenograft (PDX) models and in ex vivo cultured CTCs derived from patients with HR+breast cancer extensively treated with multiple endocrine therapies, including fulvestrant. Both CTCs and PDX models are refractory to fulvestrant but sensitive to elacestrant, independent of mutations in ESR1 and Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) genes.Elacestrant retains efficacy in breast cancer cells that have acquired resistance to currently available ER targeting therapies. Elacestrant may be an option for patients with HR+/HER2- breast cancer whose disease progressed on fulvestrant in the metastatic setting.Serial endocrine therapy is the mainstay of management for metastatic HR+breast cancer, but acquisition of drug resistance highlights the need for better therapies. Elacestrant is a recently FDA-approved novel oral selective estrogen receptor degrader (SERD), with demonstrated efficacy in the EMERALD phase 3 clinical trial of refractory HR+breast cancer. Subgroup analysis of the EMERALD clinical trial identifies clinical benefit with elacestrant in patients who had received prior fulvestrant independent of the mutational status of the ESR1 gene, supporting its potential utility in treating refractory HR+breast cancer. Here, we use pre-clinical models, including ex vivo cultures of circulating tumor cells and patient-derived xenografts, to demonstrate the efficacy of elacestrant in breast cancer cells with acquired resistance to fulvestrant." @default.
• W4380680905 created "2023-06-15" @default.
• W4380680905 creator A5004833935 @default.
• W4380680905 creator A5005286764 @default.
• W4380680905 creator A5022121965 @default.
• W4380680905 creator A5033267887 @default.
• W4380680905 creator A5034972183 @default.
• W4380680905 creator A5038280749 @default.
• W4380680905 creator A5044631743 @default.
• W4380680905 creator A5047918797 @default.
• W4380680905 creator A5048714639 @default.
• W4380680905 creator A5049730819 @default.
• W4380680905 creator A5051629490 @default.
• W4380680905 creator A5054354563 @default.
• W4380680905 creator A5061125875 @default.
• W4380680905 creator A5065034932 @default.
• W4380680905 creator A5065576841 @default.
• W4380680905 creator A5066599334 @default.
• W4380680905 creator A5069961391 @default.
• W4380680905 creator A5073955009 @default.
• W4380680905 creator A5075867487 @default.
• W4380680905 creator A5078388793 @default.
• W4380680905 creator A5084984456 @default.
• W4380680905 creator A5085370027 @default.
• W4380680905 creator A5085488691 @default.
• W4380680905 date "2023-06-15" @default.
• W4380680905 modified "2023-10-18" @default.
• W4380680905 title "Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells" @default.
• W4380680905 cites W2012987872 @default.
• W4380680905 cites W2021029132 @default.
• W4380680905 cites W2021145743 @default.
• W4380680905 cites W2062291041 @default.
• W4380680905 cites W2073367400 @default.
• W4380680905 cites W2111324624 @default.
• W4380680905 cites W2117634794 @default.
• W4380680905 cites W2119494825 @default.
• W4380680905 cites W2512004978 @default.
• W4380680905 cites W2514365970 @default.
• W4380680905 cites W2611953519 @default.
• W4380680905 cites W2765792772 @default.
• W4380680905 cites W2773461708 @default.
• W4380680905 cites W2896846857 @default.
• W4380680905 cites W2903143832 @default.
• W4380680905 cites W2957218735 @default.
• W4380680905 cites W2964142306 @default.
• W4380680905 cites W2969730643 @default.
• W4380680905 cites W2980954961 @default.
• W4380680905 cites W2982234703 @default.
• W4380680905 cites W2995918299 @default.
• W4380680905 cites W3010197652 @default.
• W4380680905 cites W3010575887 @default.
• W4380680905 cites W3015634062 @default.
• W4380680905 cites W3031565760 @default.
• W4380680905 cites W3103828236 @default.
• W4380680905 cites W3123867938 @default.
• W4380680905 cites W3130994743 @default.
• W4380680905 cites W3133509869 @default.
• W4380680905 cites W3143249818 @default.
• W4380680905 cites W3186188353 @default.
• W4380680905 cites W4221085715 @default.
• W4380680905 cites W4280490473 @default.
• W4380680905 cites W4288789298 @default.
• W4380680905 cites W4295817014 @default.
• W4380680905 cites W4322772316 @default.
• W4380680905 cites W4322772327 @default.
• W4380680905 cites W4322775295 @default.
• W4380680905 cites W4368347286 @default.
• W4380680905 doi "https://doi.org/10.1007/s10549-023-06998-w" @default.
• W4380680905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37318638" @default.
• W4380680905 hasPublicationYear "2023" @default.
• W4380680905 type Work @default.
• W4380680905 citedByCount "0" @default.
• W4380680905 crossrefType "journal-article" @default.
• W4380680905 hasAuthorship W4380680905A5004833935 @default.
• W4380680905 hasAuthorship W4380680905A5005286764 @default.
• W4380680905 hasAuthorship W4380680905A5022121965 @default.
• W4380680905 hasAuthorship W4380680905A5033267887 @default.
• W4380680905 hasAuthorship W4380680905A5034972183 @default.
• W4380680905 hasAuthorship W4380680905A5038280749 @default.
• W4380680905 hasAuthorship W4380680905A5044631743 @default.
• W4380680905 hasAuthorship W4380680905A5047918797 @default.
• W4380680905 hasAuthorship W4380680905A5048714639 @default.
• W4380680905 hasAuthorship W4380680905A5049730819 @default.
• W4380680905 hasAuthorship W4380680905A5051629490 @default.
• W4380680905 hasAuthorship W4380680905A5054354563 @default.
• W4380680905 hasAuthorship W4380680905A5061125875 @default.
• W4380680905 hasAuthorship W4380680905A5065034932 @default.
• W4380680905 hasAuthorship W4380680905A5065576841 @default.
• W4380680905 hasAuthorship W4380680905A5066599334 @default.
• W4380680905 hasAuthorship W4380680905A5069961391 @default.
• W4380680905 hasAuthorship W4380680905A5073955009 @default.
• W4380680905 hasAuthorship W4380680905A5075867487 @default.
• W4380680905 hasAuthorship W4380680905A5078388793 @default.
• W4380680905 hasAuthorship W4380680905A5084984456 @default.
• W4380680905 hasAuthorship W4380680905A5085370027 @default.
• W4380680905 hasAuthorship W4380680905A5085488691 @default.
• W4380680905 hasBestOaLocation W43806809051 @default.
• W4380680905 hasConcept C121608353 @default.
• W4380680905 hasConcept C126322002 @default.
• W4380680905 hasConcept C143998085 @default.

• next